Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41698-019-0102-5
DC FieldValue
dc.titleLiquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip
dc.contributor.authorKhoo, Bee Luan
dc.contributor.authorShang, Menglin
dc.contributor.authorNg, Chin Hin
dc.contributor.authorLim, Chwee Teck
dc.contributor.authorChng, Wee Joo
dc.contributor.authorHan, Jongyoon
dc.date.accessioned2022-07-21T06:50:57Z
dc.date.available2022-07-21T06:50:57Z
dc.date.issued2019-12-02
dc.identifier.citationKhoo, Bee Luan, Shang, Menglin, Ng, Chin Hin, Lim, Chwee Teck, Chng, Wee Joo, Han, Jongyoon (2019-12-02). Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip. NPJ PRECISION ONCOLOGY 3 (1). ScholarBank@NUS Repository. https://doi.org/10.1038/s41698-019-0102-5
dc.identifier.issn2397768X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229008
dc.description.abstractLong-term management for leukemia is challenging due to the painful and invasive procedure of bone marrow (BM) biopsy. At present, non-invasive liquid (blood) biopsy is not utilized for leukemia, due to lower counts of leukemia blast cells in the blood. Here, we described a robust system for the simultaneous detection and enrichment of rare blast cells. Enrichment of blast cells was achieved from blood with a one-step microfluidic blast cell biochip (BCB) sorting system, without specific targeting of proteins by antibodies. Non-target cells encountered a differential net force as compared to stiffer blast cells and were removed. The efficiency of the BCB promotes high detection sensitivity (1 in 106 cells) even from patients with minimal residual disease. The procedure was validated using actual blast cells from patients with various types of leukemia. Outcomes were compared to current evaluation standards, such as flow cytometry, using BM aspirates. Blast cell detection efficiency was higher in 55.6% of the patients using the BCB as compared to flow cytometry, despite the lower concentrations of blast cells in liquid biopsy. These studies promote early-stage detection and routine monitoring for minimal residual disease in patients.
dc.language.isoen
dc.publisherNATURE PUBLISHING GROUP
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectACUTE MYELOID-LEUKEMIA
dc.subjectCIRCULATING TUMOR-CELLS
dc.subjectLABEL-FREE ISOLATION
dc.subjectBONE-MARROW
dc.subjectULTRA-FAST
dc.subjectMICROFLUIDICS
dc.subjectDEFORMABILITY
dc.typeArticle
dc.date.updated2022-07-17T12:11:49Z
dc.contributor.departmentDEAN'S OFFICE (MEDICINE)
dc.contributor.departmentINST FOR HEALTH INNOVATION & TECHNOLOGY
dc.description.doi10.1038/s41698-019-0102-5
dc.description.sourcetitleNPJ PRECISION ONCOLOGY
dc.description.volume3
dc.description.issue1
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip.pdfPublished version4.04 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

16
checked on Dec 2, 2022

Page view(s)

39
checked on Dec 1, 2022

Download(s)

3
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.